Searching for your content...
Phone
877-269-7890 from 8 AM - 10 PM ET
Contact Cision
VANCOUVER, May 25, 2016 /CNW/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF), today reported financial results for the quarter ended March 31, 2016. Amounts, unless specified ...
VANCOUVER, April 14, 2016 /CNW/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF), today reported financial results for the year ended December 31, 2015. Amounts, unless...
VANCOUVER, Feb. 17, 2016 /CNW/ - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF), today announces the grant of stock options to directors, officers and consultants to the...
VANCOUVER, Jan. 18, 2016 /CNW/ - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF), today announced that effective immediately, in an effort to preserve its asset base and...
VANCOUVER, Dec. 24, 2015 /CNW/ - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF), today announced the appointment of Susan Koppy and John Meekison to iCo's Board of...
In the news release, iCo Therapeutics Announces Third Quarter 2015 Financial Results, issued today by iCo Therapeutics Inc. over CNW, we are advised by the company that in the paragraph Summary Third ...
VANCOUVER, Oct. 26, 2015 /CNW/ - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF) today announced that the company has engaged Corealis Pharma Inc. ("Corealis") a contract...
VANCOUVER, Aug. 26, 2015 /CNW/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF), today reported financial results for the quarter ended June 30, 2015. Amounts, unless specified ...
VANCOUVER, June 26, 2015 /CNW/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF), today announced that all nominees listed in the management information circular dated June 1,...
VANCOUVER, May 28, 2015 /CNW/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF), today reported financial results for the quarter ended March 31, 2015. Amounts, unless specified ...
VANCOUVER, April 27, 2015 /CNW/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF), today reported financial results for the year ended December 31, 2014. Amounts, unless...
VANCOUVER, April 17, 2015 /CNW/ - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF), at the request of IIROC, confirms that there is no material change that would account for ...
VANCOUVER, Nov. 28, 2014 /CNW/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF), today reported financial results for the nine months ended September 30, 2014. Amounts, unless...
VANCOUVER, Nov. 4, 2014 /CNW/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF), today announced that presentations regarding the company's Oral Amphotericin B drug candidate...
VANCOUVER, Oct. 22, 2014 /CNW/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF), today announced next steps for its Oral Amphotericin B program. The company recently announced...
VANCOUVER, Aug. 29, 2014 /CNW/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF), today reported financial results for the six months ended June 30, 2014. Amounts, unless...
VANCOUVER, Aug. 19, 2014 /CNW/ - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF), today reported results of its Oral Amphotericin B (Oral Amp B) drug candidate targeting...
VANCOUVER, July 15, 2014 /CNW/ - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF), at the request of IIROC, confirms that there is no material change that would account for...
VANCOUVER, June 30, 2014 /CNW/ - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF) today announced that all nominees listed in the management information circular dated May...
VANCOUVER, June 9, 2014 /CNW/ - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF) today announced top-line results related to the eight month visual acuity (VA) primary...
VANCOUVER, May 29, 2014 /CNW/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF), today reported financial results for the quarter ended March 31, 2014. Amounts, unless specified ...
VANCOUVER, April 29, 2014 /CNW/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF), today announced that research collaborators will make a poster presentation at the Association ...
VANCOUVER, April 24, 2014 /CNW/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF), today reported financial results for the year ended December 31, 2013. Amounts, unless...
VANCOUVER, March 5, 2014 /CNW/ - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF) has announced the final month eight patient visit in the iDEAL Study. This US Phase 2...
VANCOUVER, Feb. 25, 2014 /CNW/ - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF) today announced that its United States trading symbol ICOTF has received approval from The...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.